| References: |
LX2343 effectively ameliorated the cognitive deficits in APP/PS1 mice, targeting both Aβ production and clearance.LX2343 was able to ameliorate both OS and tauopathy at the same time; LX2343 substantially reduced ROS accumulation similar to an antioxidant and restored mitochondrial function through stabilizing the mitochondrial membrane potential, maintaining mitochondrial morphological integrity, and increasing ATP biosynthesis. In addition, LX2343 also suppressed hyperphosphorylation of tau by inhibition of GSK-3β. Thus, the dual effect of LX2343 has emphasized its potential for breaking the cycle of OS and tauopathy.LX2343 rescued neuronal cells from apoptosis by maintaining the integrity of mitochondrial function and morphology, alleviating OS and the JNK/p38 pathway and regulating anti- and pro-apoptotic proteins. In addition, LX2343 also potently inhibited tau hyperphosphorylation by functioning as a non-ATP competitive inhibitor of GSK-3β. |
